Dermatology
Feature
Health plans get very poor scores for access to autoimmune drugs
Three out of four insurance plans use policies that result in significant to severe restriction of access to medications for seven autoimmune...
Latest News
Secukinumab shows benefit for hidradenitis suppurativa out to 52 weeks
“In my experience, optimizing treatment can take almost a year and I hope we will see longer controlled periods in future studies,” Dr. Alexa B....
Latest News
More than 97K new cutaneous melanoma diagnoses expected in 2023
More than 1.3 million people in the United States live with cutaneous melanoma, and the overall 5-year survival is 93.7%.
Latest News
Notalgia paresthetica: Difelikefalin helps upper-back itch, but with side effects
The main side effects reported included headaches, dizziness, constipation and increased urine output.
Latest News
Isothiazolinone contact allergy up in North America, down in Europe
The study compared the prevalence of positive patch test reactions to MCI/MI and to MI alone in North America and in Europe between 2009 and 2018...
Latest News
Embattled iPLEDGE program: Changes ahead?
When the iPLEDGE program had transitioned to the new platform, the rollout was far from smooth.
Latest News
FDA expands oral JAK abrocitinib to adolescents with AD
The indication has been expanded for those aged 12-17 whose disease is not adequately controlled with other systemic drugs, including biologics,...
Opinion
A White male presented with a 1½-year history of a progressive hypoesthetic annular, hyperpigmented plaque on the upper arm
A patient presents with a subtle, solitary 4-cm annular skin-colored thin plaque on his left posterior upper arm.
Latest News
Developments in wound healing include different treatment options
The TNF blocker infliximab is among the options to consider when treating pyoderma gangrenosum, according to Hadar Lev-Tov, MD...
Latest News
Expert gives tips on less-discussed dermatologic diseases
These diseases are important not to miss and can “also be quite challenging when we think about their management.”
Latest News
First Humira biosimilar launches in U.S.
Amgen’s Amjevita will be offered at 5% and 55% below Humira’s list price, but patients may not benefit from the more significant discount.